Tamiflu U.S. Labeling Adopts Japanese Warnings
This article was originally published in PharmAsia News
Executive Summary
A spike in the number of postmarketing adverse event reports associated with Tamiflu use is prompting FDA staff to recommend adoption of international labeling for the antiviral